Results from the Phase III NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) trials demonstrated that ianalumab ...

Novartis is hoping to gain approval for its Sjögren’s disease drug after it met the endpoints in two Phase III trials. The ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

A former director of Chinook Therapeutics Inc. tipped off family and friends who traded stock ahead of an announcement that ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Novartis AG said an experimental medicine helped patients with an autoimmune disease in late-stage studies, offering a boost ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

The pharma company said the drug has the potential to become the first and only targeted treatment approved for patients with ...

Pre-tax profits at the Irish arm of Swiss-headquartered pharmaceutical giant, Novartis, last year declined by 25% to €8m as ...

Novartis AG NOVN 1.25% launched a lottery-style program to provide doses of its pricey gene therapy free of charge, drawing criticism from patient groups that called it an inappropriate way to ...

Vas Narasimhan, chief executive officer of Novartis AG, in a 2018 photo. Narasimhan assumed the reigns as CEO a year ago, emphasizing the importance of digital and data for pharma R&D.